

TABLE OF CONTENTS

INTRODUCTION		1
PART I	CANCER STATISTICS: SOME FACTS	3
	Chapter 1 <i>Assessing the magnitude of the problem</i>	3
	1 <i>Cancer statistics</i>	4
	2 <i>Cancer prevalence in the US, 1998</i>	8
	3 <i>Historical trends in cancer incidence, mortality, and survival 1930-1999</i>	9
	Chapter 2 <i>The problem is growing, not going away</i>	13
PART II	WHAT IS CANCER?	14
	Chapter 3 <i>Cancer through the ages</i>	14
	1 <i>From ancient Egypt to Greece and Rome</i>	14
	2 <i>The middle ages: Byzantium, the Muslims, and the pre-Renaissance</i>	16
	3 <i>From the Renaissance to World War II</i>	17
	Chapter 4 <i>Our current understanding</i>	27
	1 <i>The genetic basis of cancer</i>	27
	2 <i>How does cancer arise?</i>	43
	3 <i>How does cancer spread?</i>	50
PART III	HOW IS CANCER TREATED?	53
	Chapter 5 <i>The cancer-cell kill paradigm: Hypotheses and corollaries</i>	53
	Chapter 6 <i>Chemotherapy drugs</i>	61
	1 <i>Historical background: Mustard gas</i>	61
	2 <i>Fifty years of drug discovery: The role of serendipity and trial & error</i>	64
	3 <i>Forty years of attempts to overcome cancer drug inefficacy</i>	68
	Chapter 7 <i>Treatment outcomes: Dismal by any standard</i>	80
PART IV	WHY DOES THIS SYSTEM PERSIST?	86
	Chapter 8 <i>The role of the National Cancer Institute</i>	87
	1 <i>Historical Background</i>	87
	2 <i>Current organization, role and influence</i>	92
	3 <i>Cancer centers program</i>	93
	4 <i>Cooperative Trials Structure</i>	94
	5 <i>Clinical trials</i>	97
	Chapter 9 <i>Publications: The facts and nothing but the facts?</i>	105
	Chapter 10 <i>From the doctors' perspective</i>	112
	1 <i>Physicians qualifications</i>	112
	2 <i>Factors that dictate cancer treatment</i>	117
	Chapter 11 <i>From the patients' perspective</i>	127
	1 <i>Patients' perceptions and expectations</i>	127
	2 <i>Facing hard choices</i>	136
PART V	WHERE DO WE GO FROM HERE?	147
	Chapter 12 <i>A vision for the future</i>	147
	1 <i>Cancer prevention</i>	149
	2 <i>Cancer screening</i>	161
	3 <i>When prevention and screening fail: Molecularly targeted drugs</i>	172
	Chapter 13 <i>Shifting from the cell-kill paradigm to molecular therapies</i>	181
	1 <i>A blueprint for future clinical cancer research</i>	182
	2 <i>A blueprint for future patient management</i>	188
CONCLUSIONS		194
REFERENCES		198
GLOSSARY		235
INDEX		249